153 related articles for article (PubMed ID: 35484651)
1. Low-dose tyrosine kinase inhibitors in patients with chronic myeloid leukemia: a retrospective study in China.
Chen Y; Liu Z; Zou J; Wang D; He W; Meng L; Cheng F; Zhang Y; Li W
Haematologica; 2022 Aug; 107(8):1966-1970. PubMed ID: 35484651
[No Abstract] [Full Text] [Related]
2. PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia.
Wolff NC; Veach DR; Tong WP; Bornmann WG; Clarkson B; Ilaria RL
Blood; 2005 May; 105(10):3995-4003. PubMed ID: 15657179
[TBL] [Abstract][Full Text] [Related]
3. Does switching to a second-generation tyrosine kinase inhibitor or increasing imatinib dose have long-term benefits in chronic myeloid leukemia patients with suboptimal responses under upfront standard-dose of imatinib?
Eskazan AE; Tiribelli M
Leuk Res; 2018 Nov; 74():55-56. PubMed ID: 30296661
[No Abstract] [Full Text] [Related]
4. Imatinib mesylate in chronic myeloid leukemia: frontline treatment and long-term outcomes.
Stagno F; Stella S; Spitaleri A; Pennisi MS; Di Raimondo F; Vigneri P
Expert Rev Anticancer Ther; 2016; 16(3):273-8. PubMed ID: 26852913
[TBL] [Abstract][Full Text] [Related]
5. [Therapeutic drug management of BCR-ABL tyrosine kinase inhibitor for chronic myeloid leukemia patients].
Miura M; Takahashi N
Rinsho Ketsueki; 2013 Oct; 54(10):1720-9. PubMed ID: 24064822
[No Abstract] [Full Text] [Related]
6. [MET/ERK and MET/JNK Pathway Activation Is Involved in BCR-ABL Inhibitor-resistance in Chronic Myeloid Leukemia].
Tsubaki M
Yakugaku Zasshi; 2018; 138(12):1461-1466. PubMed ID: 30504658
[TBL] [Abstract][Full Text] [Related]
7. Treatment of chronic myeloid leukemia with imatinib mesylate.
Ohno R
Int J Clin Oncol; 2006 Jun; 11(3):176-83. PubMed ID: 16850123
[TBL] [Abstract][Full Text] [Related]
8. Molecular monitoring of response to imatinib (Glivec) in chronic myeloid leukemia patients: experience at a tertiary care hospital in Saudi Arabia.
Khalil SH; Abu-Amero KK; Al Mohareb F; Chaudhri NA
Genet Test Mol Biomarkers; 2010 Feb; 14(1):67-74. PubMed ID: 19943786
[TBL] [Abstract][Full Text] [Related]
9. Development of plasma cell leukemia in a patient with chronic myeloid leukemia while on treatment with imatinib mesylate.
Maral S; Bakanay SM; Yikilmaz AS; Dilek I
J Cancer Res Ther; 2018; 14(6):1431-1433. PubMed ID: 30488870
[TBL] [Abstract][Full Text] [Related]
10. BCR-ABL mutational studies for predicting the response of patients with chronic myeloid leukaemia to second-generation tyrosine kinase inhibitors after imatinib failure.
Kwan TK; Ma ES; Chan YY; Wan TS; Liu HS; Sim JP; Yeung YM; Lie AK; Yip SF
Hong Kong Med J; 2009 Oct; 15(5):365-73. PubMed ID: 19801694
[TBL] [Abstract][Full Text] [Related]
11. Delayed resistance to imatinib after 16 years of therapy in a patient with chronic myeloid leukaemia.
Kaur U; Gambhir IS; Khare VR; Singh A; Chakrabarti SS
Br J Haematol; 2020 Jul; 190(1):e51-e53. PubMed ID: 32400888
[No Abstract] [Full Text] [Related]
12. Glucose availability in hypoxia regulates the selection of chronic myeloid leukemia progenitor subsets with different resistance to imatinib-mesylate.
Giuntoli S; Tanturli M; Di Gesualdo F; Barbetti V; Rovida E; Dello Sbarba P
Haematologica; 2011 Feb; 96(2):204-12. PubMed ID: 21071498
[TBL] [Abstract][Full Text] [Related]
13. Targeting Stem Cells in Chronic Myeloid Leukemia with a PPAR-γ Agonist.
Egan JM
N Engl J Med; 2015 Nov; 373(20):1973-5. PubMed ID: 26559576
[TBL] [Abstract][Full Text] [Related]
14. Choosing the best second-line tyrosine kinase inhibitor in imatinib-resistant chronic myeloid leukemia patients harboring Bcr-Abl kinase domain mutations: how reliable is the IC₅₀?
Soverini S; Rosti G; Iacobucci I; Baccarani M; Martinelli G
Oncologist; 2011; 16(6):868-76. PubMed ID: 21632458
[TBL] [Abstract][Full Text] [Related]
15. Molecular studies in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors.
Sawyers CL
Semin Hematol; 2001 Jul; 38(3 Suppl 8):15-21. PubMed ID: 11526597
[TBL] [Abstract][Full Text] [Related]
16. BCR-ABL tyrosine kinase inhibitors for chronic myelogenous leukemia.
Schiffer CA
N Engl J Med; 2007 Jul; 357(3):258-65. PubMed ID: 17634461
[No Abstract] [Full Text] [Related]
17. Improved Drug Adherence in Patients with Chronic Myeloid Leukemia in the Chronic Phase by Switching to Second-Generation Tyrosine Kinase Inhibitors.
Maeda Y; Okamoto A; Kawaguchi SI; Konishi A; Yamamoto K; Eguchi G; Kanai Y; Yamaguchi T
Acta Haematol; 2017; 138(3):140-142. PubMed ID: 28869927
[No Abstract] [Full Text] [Related]
18. Adherence to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: The Challenge That Lies Ahead.
Amitai I; Leader A; Raanani P
Acta Haematol; 2016; 136(1):43-4. PubMed ID: 27160309
[No Abstract] [Full Text] [Related]
19. Switching to second-generation tyrosine kinase inhibitor improves the response and outcome of frontline imatinib-treated patients with chronic myeloid leukemia with more than 10% of BCR-ABL/ABL ratio at 3 months.
Casado LF; García-Gutiérrez JV; Massagué I; Giraldo P; Pérez-Encinas M; de Paz R; Martínez-López J; Bautista G; Osorio S; Requena MJ; Palomera L; Peñarrubia MJ; Calle C; Hernández-Rivas JÁ; Burgaleta C; Maestro B; García-Ormeña N; Steegmann JL
Cancer Med; 2015 Jul; 4(7):995-1002. PubMed ID: 25756742
[TBL] [Abstract][Full Text] [Related]
20. Imatinib-treated chronic myeloid leukemia patients with discordant response between cytogenetic and molecular tests at 3 and 6 month time-points have a reduced probability of subsequent optimal response.
Bonifacio M; Binotto G; Maino E; Calistri E; Marin L; Scaffidi L; Frison L; De Marchi F; Krampera M; Semenzato G; Fanin R; Ambrosetti A; Tiribelli M;
Haematologica; 2015 Aug; 100(8):e299-301. PubMed ID: 25820333
[No Abstract] [Full Text] [Related]
[Next] [New Search]
